Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Afshan Adil"'
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 96-100 (2024)
Introduction: Chronic myeloid leukemia (CML) is characterized by the presence of the BCR::ABL1 fusion gene, and the advent of tyrosine kinase inhibitors (TKIs) has revolutionized its therapeutic landscape. Asciminib, a STAMP inhibitor, emerges as a p
Externí odkaz:
https://doaj.org/article/6fc7a1e3a31844ef9c8f1576aebc59a0
Autor:
Alshurafa A; Hematology Department, Hamad Medical Corporation, Doha, Qatar., Afshan Adil; Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar., Yassin MA; Hematology Department, Hamad Medical Corporation, Doha, Qatar.
Publikováno v:
Case reports in oncology [Case Rep Oncol] 2024 Jan 16; Vol. 17 (1), pp. 96-100. Date of Electronic Publication: 2024 Jan 16 (Print Publication: 2024).